[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636469":3},{"organization":4,"outcomesModule":7,"designInfo":73,"detailedDescription":76,"studyPopulation":76,"armGroups":83,"interventions":96,"overallOfficials":76,"centralContacts":104,"locations":110,"responsibleParty":126,"collaborators":130,"id":134,"slug":76,"hasResults":135,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":135,"sex":140,"minAge":141,"maxAge":76,"enrollmentInfo":142,"targetDuration":76,"studyType":145,"phases":146,"briefSummary":148,"conditions":149,"keywords":151,"overallStatus":158,"whyStopped":76,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":168},{"fullName":5,"class":6},"Asan Medical Center","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":63},[9],{"measure":10,"description":11,"timeFrame":12},"The event rate of Target Lesion Failure","Target Lesion Failure is defined as a composite of cardiovascular death, target vessel myocardial infarction, and clinically driven target-lesion revascularization.","1 year",[14,17,20,23,25,27,29,32,34,36,39,41,43,46,48,51,53,55,57,59,61],{"measure":15,"description":16,"timeFrame":12},"The event rate of Device success","Acute Success Endpoints\\_lesion level",{"measure":18,"description":19,"timeFrame":12},"The event rate of Procedural success","Acute Success Endpoints\\_patient level",{"measure":21,"description":22,"timeFrame":12},"The event rate of Death from any causes","Major Composite Clinical Endpoints\\_Patient-Oriented Clinical Endpoint, POCE",{"measure":24,"description":22,"timeFrame":12},"The event rate of Any stroke",{"measure":26,"description":22,"timeFrame":12},"The event rate of Any myocardial infarction",{"measure":28,"description":22,"timeFrame":12},"The event rate of Any repeat revascularization",{"measure":30,"description":31,"timeFrame":12},"The event rate of Cardiovascular death","Major Composite Clinical Endpoints\\_Target Vessel Failure",{"measure":33,"description":31,"timeFrame":12},"The event rate of Target vessel myocardial infarction",{"measure":35,"description":31,"timeFrame":12},"The event rate of Target vessel revascularization",{"measure":37,"description":38,"timeFrame":12},"The event rate of All-cause death","Individual Clinical Endpoints\\_Mortality",{"measure":40,"description":38,"timeFrame":12},"The event rate of Cardiac death",{"measure":42,"description":38,"timeFrame":12},"The event rate of Non-cardiac death",{"measure":44,"description":45,"timeFrame":12},"The event rate of All myocardial infarction including Q wave and Non-Q wave","Individual Clinical Endpoints\\_Myocardial Infarction",{"measure":47,"description":45,"timeFrame":12},"The event rate of Non-target vessel myocardial infarction",{"measure":49,"description":50,"timeFrame":12},"The event rate of All revascularization","Individual Clinical Endpoints\\_Revascularization",{"measure":52,"description":50,"timeFrame":12},"The event rate of All target lesion revascularization",{"measure":54,"description":50,"timeFrame":12},"The event rate of All target vessel revascularization",{"measure":56,"description":50,"timeFrame":12},"The event rate of Non-target vessel revascularization",{"measure":24,"description":58,"timeFrame":12},"Individual Clinical Endpoints\\_Stroke",{"measure":60,"description":58,"timeFrame":12},"The event rate of Ischemic stroke",{"measure":62,"description":58,"timeFrame":12},"The event rate of Hemorrhagic stroke",[64,67,69,71],{"measure":65,"description":66,"timeFrame":12},"The event rate of Definite or probable stent thrombosis","Safety Endpoints",{"measure":68,"description":66,"timeFrame":12},"The event rate of Definite stent thrombosis",{"measure":70,"description":66,"timeFrame":12},"The event rate of Probable stent thrombosis",{"measure":72,"description":66,"timeFrame":12},"The event rate of The Bleeding Academic Research Consortium (BARC) type 2, 3, 4, 5",{"allocation":74,"interventionModel":75,"interventionModelDescription":76,"primaryPurpose":77,"observationalModel":76,"timePerspective":76,"maskingInfo":78},"RANDOMIZED","PARALLEL",null,"TREATMENT",{"masking":79,"maskingDescription":76,"whoMasked":80},"DOUBLE",[81,82],"PARTICIPANT","OUTCOMES_ASSESSOR",[84,90],{"label":85,"type":86,"description":87,"interventionNames":88},"Sirolimus-Ascorbic Acid Eluting Stent","EXPERIMENTAL","D+STORM NOVONIX stent",[89],"Device: Sirolimus-Ascorbic Acid Eluting Stent",{"label":91,"type":92,"description":93,"interventionNames":94},"Everolimus-Eluting Stent","ACTIVE_COMPARATOR","SYNERGY XD",[95],"Device: Everolimus-Eluting Stent",[97,101],{"type":98,"name":85,"description":99,"armGroupLabels":100,"otherNames":76},"DEVICE","bioabsorbable polymer Sirolimus-Ascorbic Acid Eluting Stent",[85],{"type":98,"name":91,"description":102,"armGroupLabels":103,"otherNames":76},"bioabsorbable polymer everolimus-eluting stent",[91],[105],{"name":106,"role":107,"phone":108,"phoneExt":76,"email":109},"Jung-hee Ham Project Manager, Registered Nurse","CONTACT","82-2-3010-4728","cvcrc5@amc.seoul.kr",[111],{"facility":5,"status":76,"city":112,"state":76,"zip":76,"country":113,"countryCode":76,"cosmosGeoPoint":114,"geoPoint":119,"contacts":120},"Seoul","South Korea",{"type":115,"coordinates":116},"Point",[117,118],126.9784,37.566,{"lat":118,"lon":117},[121,123],{"name":122,"role":107,"phone":108,"phoneExt":76,"email":109},"Jung-min Ahn, MD",{"name":124,"role":125,"phone":76,"phoneExt":76,"email":76},"Jung-min Ahn, MD, PhD","PRINCIPAL_INVESTIGATOR",{"type":127,"investigatorFullName":128,"investigatorTitle":129,"investigatorAffiliation":5,"oldNameTitle":76,"oldOrganization":76},"SPONSOR_INVESTIGATOR","Jung-min Ahn","Professor in Department of Cardiology, Asan Medical Center",[131],{"name":132,"class":133},"The CardioVascular Research Foundation (CVRF)","UNKNOWN","100636469",false,"NCT07566091","Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers","NOVA","Inclusion Criteria:\n\n1. Adult men and women aged 19 years or older\n2. Patients with chronic coronary syndrome (CCS) or acute coronary syndrome (ACS) who require percutaneous coronary intervention (PCI) (all-comers)\n3. Patients who have voluntarily provided written informed consent to participate in the study\n\nExclusion Criteria:\n\n1. Cardiogenic shock within 48 hours prior to the procedure\n2. Known hypersensitivity to sirolimus, everolimus, ascorbic acid, or stent components (e.g., cobalt-chromium alloy)\n3. Patients unable to maintain dual antiplatelet therapy (DAPT), including aspirin and a P2Y12 inhibitor, for 1 year\n4. Women who are pregnant, breastfeeding, or of childbearing potential\n5. Clinically significant abnormalities identified during study visits, physical examination, laboratory tests, or electrocardiogram (ECG) that, in the investigator's judgment, may interfere with the safe completion of the study\n6. Life expectancy of less than 1 year or presence of serious non-cardiac conditions that may affect compliance with the study protocol\n7. Patients who are unwilling or unable to comply with the study protocol","ALL","19 Years",{"count":143,"type":144},2034,"ESTIMATED","INTERVENTIONAL",[147],"NA","The objective of this study is to demonstrate the primary hypothesis that, in patients with chronic and acute coronary syndromes requiring percutaneous coronary intervention (PCI), the novel sirolimus-ascorbic acid eluting stent (D+Storm Novonix) is non-inferior to the standard treatment, the everolimus-eluting stent (Synergy XD), with respect to the incidence of target lesion failure (TLF) at 1 year after treatment, where TLF is defined as a composite of cardiovascular death, target vessel myocardial infarction, and clinically driven target-lesion revascularization.",[150],"Coronary Artery Disease",[152,153,154,155,156,157],"acute coronary syndrome","chronic coronary syndrome","D+Storm Novonix","sirolimus-ascorbic acid eluting stent","everolimus-eluting stent","percutaneous coronary intervention","NOT_YET_RECRUITING","2026-04-27",{"date":161,"type":162},"2026-05-04","ACTUAL",{"date":164,"type":144},"2026-06-15",{"date":166,"type":144},"2028-06-15",{"name":128,"class":6},1]